FDA grants priority review to mosunetuzumab for relapsed or refractory follicular lymphoma
The FDA granted priority review to mosunetuzumab for treatment of certain patients with relapsed or refractory follicular lymphoma.The designation applies to use of the agent by adults who received at least two prior systemic therapies.